Archive: Company News
Company News: Results of Phase II Combination Trial of ISA101 and Nivolumab to be Presented at ESMO 2017
– Incurable HPV16+ solid tumors treated with therapeutic cancer vaccine plus checkpoint inhibitor
ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company, today announced the presentation of the results of a clinical Phase II trial initiated by MD Anderson Cancer Center in collaboration with ISA and Bristol-Myers Squibb (NCT02426892) at ESMO 2017 (September 8-12, 2017, Madrid, Spain). In the trial, cancer patients with HPV16+ incurable solid tumors received a combination of ISA’s synthetic long-peptide (SLP) HPV-16 vaccine ISA101 and nivolumab, a monoclonal antibody acting as a PD-1 checkpoint inhibitor.
Company News: Curetis Announces Financial Results for the First Six Months of 2017
– Further advancement of product pipeline and integration of GEAR and Gyronimo platforms
– Expansion of global installed base to 161 as of June 30, 2017; 42.5% increase over prior year
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today reported its financial results for the first six months ended June 30, 2017, and provided an update on its financial and business guidance for the second half of 2017 and beyond.
Company News: Curetis Announces Management Board Changes
– New roles for Andreas Boos, Chris Bernard and Dr. Achim Plum
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced several changes in its Management Board, effective as of today.
Company News: Curetis Partners with Biotest to support academic PEPPER Pentaglobin® Peritonitis Trial with Unyvero IAI Application
— Trial sponsored by University Clinic RWTH Aachen investigates personalized treatment approaches with Biotest’s Pentaglobin® in peritonitis patients
— Curetis to provide testing services for different samples from up to 200 patients with its recently launched Unyvero IAI Application for intra-abdominal infections
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that it has closed a partnership with Biotest AG (Dreieich, Germany). Under the terms of the agreement, Curetis will provide Biotest with in-house testing services using Curetis’ Unyvero IAI cartridge for the diagnosis of intra-abdominal infections. Financial terms were not disclosed.